PDF) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Daniele MARTINELLI | PhD Student | Doctor of Medicine | University of Pavia, Pavia | UNIPV | Department of Brain and Behavioral Sciences | Research profile
Does erenumab suspension affect chronic migraine course? A real life experience
Does erenumab suspension affect chronic migraine course? A real life experience
CONCLUSIONS BACKGROUND OBJECTIVE METHODS RESULTS REFERENCES ACKNOWLEDGEMENTS RESULTS (CONTINUED)
Migraine: integrated approaches to clinical management and emerging treatments - The Lancet
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine: Expert Opinion on Drug Safety: Vol 20, No 4
PDF) Migraine and COVID-19 lockdown
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
60th Annual Scientific Meeting American Headache Society® June 28‐July 1, 2018 San Francisco Marriott Marquis San Francisco, CA - 2018 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Getting closer to a cure for migraine | Nature Reviews Neurology
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
